003060 — Aprogen Biologics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Aprogen Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	53,320	56,482	65,190	87,364	67,378
Cost of Revenue
Gross Profit	23,201	25,445	27,286	-11,663	-7,579
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	56,170	62,420	71,895	151,321	137,483
Operating Profit	-2,850	-5,938	-6,704	-63,957	-70,105
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,644	9,831	14,881	-113,383	-104,980
Provision for Income Taxes
Net Income After Taxes	18,918	9,151	13,621	-115,330	-104,980
Minority Interest
Net Income Before Extraordinary Items
Net Income	11,253	8,103	12,639	-118,270	-104,979
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	11,253	8,103	12,639	-118,270	-104,979
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	274	192	260	-1,377	-697
Dividends per Share